en · de · es · fr · pt
sr9009-notes.peptides9000.com › Topic › Background And Research Status — Background and Details

Background And Research Status — Background and Details

By Editorial Desk · published 2025-08-22 · last reviewed 2025-10-11 · Topic

SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Related pages on this site

Supporting material

Heavy ions can also be generated with an ion gun which typically uses the thermionic emission of electrons to ionize a substance in its gaseous state. Such instruments are typically used for surface analysis. Gas flows through the ion source between the anode and the cathode. A positive voltage is applied to the anode. This voltage, combined with the high magnetic field between the tips of the internal and external cathodes allow a plasma to start. Ions from the plasma are repelled by the anode's electric field. This creates an ion beam.

=== Supplantation of the ice trade === The ice trade was an industry in the 19th and 20th centuries of the harvesting, transportation, and sale of natural and artificial ice for the purposes of refrigeration and consumption. The majority of the ice used for trade was harvested from North America and transported globally with some smaller operations working out of Norway. With the introduction of more affordable large and home scale refrigeration around the 1920s, the need for large scale ice harvest and transportation was no longer needed, and the ice trade subsequently slowed and shrank to smaller scale local services or disappeared altogether.

== Creation == Their lineage dates back to include more than 200 years of unconventional warfare history, with notable predecessors including the American Revolutionary War "Swamp Fox" Francis Marion, Benjamin Forsyth in the War of 1812, Frederick Funston of the Philippine–American War, the WWII OSS Jedburgh Teams, OSS Detachment 101 in Burma, the Alamo Scouts, Colt Terry of the Korean War, and Vietnam War United States Army Special Forces officer Richard J. Meadows. Some of the Office of Strategic Services were similar in terms of the mission with the original U.S. Army Special Forces function, unconventional warfare (UW), acting as cadre to train and lead guerrillas in occupied countries. The Special Forces motto, De oppresso liber (Latin: "to free the oppressed") reflects this historical mission of guerrilla warfare against an occupying power. Specifically, the three-man Jedburgh teams provided leadership to French Resistance units. The larger Office of Strategic Services "OSS" Operational Groups (OG) were more associated with Strategic Reconnaissance/Direct Action (SR/DA) missions, although they did work with resistance units. Another unit widely associated with the origins of the Army Special Forces was the First Special Service Force, a joint Canadian-American unit formed in 1942 and disbanded in 1944. Members of the First Special Service Force were retroactively awarded the Special Forces Tab upon its creation in 1983 for their part in Special Forces' history.

11B Infantryman (includes soldiers formerly designated 11M [Mechanized] and 11H [Anti-armor]) 11B Infantryman is the basic infantry soldier MOS of the US Army. 11C Indirect Fire Infantryman (Mortarman) 11X Undetermined Infantry (Open Enlistment Option, B/C determined during training.) 11Z Infantry Senior Sergeant

JDTic is a selective, long-acting ("inactivating") antagonist of the κ-opioid receptor (KOR). JDTic is a 4-phenylpiperidine derivative, distantly related structurally to analgesics such as pethidine and ketobemidone, and more closely to the MOR antagonist alvimopan. In addition, it is structurally distinct from other KOR antagonists such as norbinaltorphimine. JDTic has been used to create crystal structures of KOR [ PDB: 4DJH, 6VI4​].

Sources: en.wikipedia.org

Notes from published material

== Commonly monitored vaccines == The vaccine vial monitor is intended for use on vaccines which may travel outside of the cold chain, but its use on certain vaccines has had an especially notable impact.

=== Influence of temperature, relative humidity and rate of air circulation === The external drying conditions (temperature, relative humidity and air velocity) control the external boundary conditions for drying, and hence the drying rate, as well as affecting the rate of internal moisture movement. The drying rate is affected by external drying conditions, as will now be described.

While Operation Hooper was underway in late January 1988, Crocker relented to pressure and accepted Cuba as an equal partner in further peace talks. Castro agreed that he would not introduce extraneous issues to the agenda, such as Cuba–US relations, and that discussion of a phased troop withdrawal would extend to all Cuban military personnel stationed in Angola, including combat troops, logistical staff, and advisers. With Cuba's entry into the Brazzaville talks, its desire to shift its military involvement in Angola from a passive, defensive role to an offensive one intensified. Castro opted to escalate ground operations against the SADF, since he considered diplomatic progress impossible as long as South Africa still clung to the likelihood of a tactical victory. He retained a solely defensive posture at Cuito Cuanavale, keeping the SADF fixed in place, while carrying out his longstanding proposal to launch a flanking manoeuvre towards the South West African border. The new offensive would consist of a movement of Cuban forces in divisional strength west of the Cunene River. On 9 March, Castro ordered all Cuban troops massed at Lobito, which had grown to about 40,000 men, southward. He likened their movement to "a boxer who with his left hand blocks the blow [at Cuito Cuanavale] and with his right – strikes [in the west]".

nucleus pl. nuclei A large spherical or lobular organelle surrounded by a dedicated membrane which functions as the main storage compartment for the genetic material of eukaryotic cells, including the DNA comprising chromosomes, as well as the site of RNA synthesis during transcription. The vast majority of eukaryotic cells have a single nucleus, though some cells may have more than one nucleus, either temporarily or permanently, and in some organisms there exist certain cell types (e.g. mammalian erythrocytes) which lose their nuclei upon reaching maturity, effectively becoming anucleate. The nucleus is one of the defining features of eukaryotes; the cells of prokaryotes such as bacteria lack nuclei entirely.

Healthcare in Romania is mainly provided by the public sector, which runs most hospitals and offers national health insurance to nearly all citizens. In 2021, healthcare costs were US$16. 7 billion, or US$2,385 per person, making up €5.69 of GDP. Government spending is higher than in markets like Bulgaria but lower than Hungary. Spending is expected to rise by 7. US$5 billion (+37. 68%) from 2024 to 2028, reaching 27. US$3 billion by 2028. The Romanian National Institute of Statistics reports over 65,000 health units in Romania, with 53,000 in urban areas and 12,000 in rural areas. There are 543 hospitals, including 488 in urban and 55 in rural areas, along with 160 other hospital-like establishments. Nearly 50% of these are large facilities with over 100 beds, while 39% are small with fewer than 50 beds. The total number of inpatient beds is 135,085, allocated mainly to psychiatry, surgery, and internal medicine among other specialties.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network